Literature DB >> 25618241

TGF-β and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells.

Xiao-Hui Chen1, Zong-Cai Liu1, Ge Zhang1, Wei Wei1, Xiao-Xiong Wang2, Hao Wang1, Hong-Peng Ke1, Fan Zhang1, Hong-Sheng Wang3, Shao-Hui Cai4, Jun Du5.   

Abstract

Human leukocyte antigen class I antigens (HLA-I) is essential in immune response by presenting antigenic peptides to cytotoxic T lymphocytes. Downregulation of HLA-I is observed in primary and metastatic prostate cancers, which facilitates them escape from immune surveillance, thereby promotes prostate cancer progression. In addition, elevated level of growth factors like TGF-β or EGF in microenvironment is related to the prostate cancer deterioration. Thus, we wondered whether TGF-β or EGF was involved in the regulation of HLA-I during the development of prostate cancer cells. In this study, we demonstrated that TGF-β and EGF both downregulated the expression of HLA-I, thereby attenuated the cytotoxic T cell mediated lysis of prostate cancer cells. Next, we revealed that TGF-β and EGF induced downregulation of HLA-I is associated with classical epithelial-mesenchymal transition (EMT) morphological changes and expression profiles. We further illustrated that overexpression of Snail is crucial for HLA-I downregulation and its association with EMT. At last, we discussed that NF-κB/p65 is the plausible target for Snail to induce HLA-I downregulation. Taken together, this is the first evidence to reveal that both TGF-β and EGF can induce HLA-I downregulation which is then proven to be associated with EMT in prostate cancer cells. These discoveries provide a deeper understanding of growth factors induced immune escape and introduce potential therapeutic targets for prostate cancers.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epithelial-mesenchymal transition (EMT); HLA-I; Immune escape; Prostate cancer; Snail

Mesh:

Substances:

Year:  2015        PMID: 25618241     DOI: 10.1016/j.molimm.2014.12.017

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  29 in total

Review 1.  Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.

Authors:  Anna E Kersh; Spencer Ng; Yun Min Chang; Maiko Sasaki; Susan N Thomas; Haydn T Kissick; Gregory B Lesinski; Ragini R Kudchadkar; Edmund K Waller; Brian P Pollack
Journal:  J Clin Pharmacol       Date:  2017-11-14       Impact factor: 3.126

2.  MicroRNA-129-5p modulates epithelial-to-mesenchymal transition by targeting SIP1 and SOX4 during peritoneal dialysis.

Authors:  Li Xiao; Xun Zhou; Fuyou Liu; Chun Hu; Xuejing Zhu; Ying Luo; Ming Wang; Xiaoxuan Xu; Shikun Yang; Yashpal S Kanwar; Lin Sun
Journal:  Lab Invest       Date:  2015-05-11       Impact factor: 5.662

Review 3.  Antitumour immunity regulated by aberrant ERBB family signalling.

Authors:  Shogo Kumagai; Shohei Koyama; Hiroyoshi Nishikawa
Journal:  Nat Rev Cancer       Date:  2021-01-18       Impact factor: 60.716

Review 4.  Signaling Pathways and Targeted Therapies for Stem Cells in Prostate Cancer.

Authors:  Madhuvanthi Giridharan; Vasu Rupani; Satarupa Banerjee
Journal:  ACS Pharmacol Transl Sci       Date:  2022-03-30

Review 5.  HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy.

Authors:  Luke Maggs; Ananthan Sadagopan; Ali Sanjari Moghaddam; Soldano Ferrone
Journal:  Trends Cancer       Date:  2021-09-03

6.  Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy.

Authors:  Riki Okita; Yuka Mimura-Kimura; Nobutaka Kawamoto; Naoki Yamamoto; Masashi Umeda; Masanori Okada; Hidetoshi Inokawa; Yusuke Mimura; Tomoyuki Murakami; Masao Nakata; Kazunori Okabe
Journal:  Cancer Immunol Immunother       Date:  2022-09-17       Impact factor: 6.630

7.  Major histocompatibility complex class I molecule expression by pancreatic cancer cells is regulated by activation and inhibition of the epidermal growth factor receptor.

Authors:  Shelby M Knoche; Alaina C Larson; Gabrielle L Brumfield; Steven Cate; William H Hildebrand; Joyce C Solheim
Journal:  Immunol Res       Date:  2022-03-18       Impact factor: 4.505

8.  Prostate cancer health disparities: An immuno-biological perspective.

Authors:  Sanjay Kumar; Rajesh Singh; Shalie Malik; Upender Manne; Manoj Mishra
Journal:  Cancer Lett       Date:  2017-11-15       Impact factor: 8.679

9.  Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells.

Authors:  Karthikeyan Subbarayan; Sandra Leisz; Claudia Wickenhauser; Daniel Bethmann; Chiara Massa; André Steven; Barbara Seliger
Journal:  Oncoimmunology       Date:  2018-01-16       Impact factor: 8.110

10.  Identification and characterization of the gene expression profiles for protein coding and non-coding RNAs of pancreatic ductal adenocarcinomas.

Authors:  María Laura Gutiérrez; Luis Corchete; Cristina Teodosio; María Eugenia Sarasquete; María del Mar Abad; Manuel Iglesias; Carmen Esteban; José María Sayagues; Alberto Orfao; Luis Muñoz-Bellvis
Journal:  Oncotarget       Date:  2015-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.